凱龍股份(002783.SZ):取得證監會配股核准批覆文件及確認終止配股
格隆匯1月28日丨凱龍股份(002783.SZ)公佈,公司於近日收到中國證監會出具的《關於核准湖北凱龍化工集團股份有限公司配股的批覆》(證監許可[2021]166號)文件。
在取得上述核准批文之前,公司已於2021年1月14日召開第七屆董事會第四十三次會議、第七屆監事會第二十五次會議,審議並通過了《關於終止公司2020年度配股公開發行證券方案的議案》,同意公司終止2020年度配股公開發行證券,公司獨立董事發表了同意公司終止該次配股事項的獨立意見。
公司確認將終止該次配股,且終止該次配股不會對公司生產經營情況及持續發展造成不利影響,不會損害公司及公司股東、特別是中小股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.